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T
he National Heart, Lung, and Blood Institute (NHLBI) con-
vened a Working Group on January 7, 2011, at George
Washington University in Washington, DC, to provide recom-
mendations to the NHLBI that would guide informed decisions
on research directions and priorities in the ﬁeld of cardiovas-
cular pharmacogenomics. This meeting was timed to follow
the New Frontiers in Personalized Medicine: Cardiovascular Re-
search and Clinical Care conference held the previous day and
cosponsored by the NHLBI, Personalized Medicine Coalition,
American College of Cardiology, American Medical Associa-
tion, and Cheney Cardiovascular Institute at George Washing-
ton University. The conference brought together leaders from
academia, industry, and government to (1) discuss personal-
izedmedicine’scurrentandpotentialimpactoncardiovascular
patient outcomes; (2) review emerging technologies and appli-
cations that may shape the ﬁeld in the future; (3) discuss the
results of an American College of Cardiology survey examining
personalized medicine adoption rates among US cardiologists;
(4)identifythebarrierstoadoptionofpharmacogenetics-based
personalized medicine in cardiovascular practice; and (5) de-
velop recommendations for next steps with an emphasis on
actions and evidence generation that are needed for adoption
and improved quality of cardiovascular patient care.
The goals of the NHLBI Working Group were to review the
discussion and recommendations from the New Frontiers in
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Personalized Medicine: Cardiovascular Research and Clinical
Care conference; to identify areas and challenges that should
be addressed to further the ﬁeld of cardiovascular pharma-
cogenomics and increase its adoption into the clinical setting;
to develop recommendations and priorities for implementing
current pharmacogenomics-based treatment modalities; and
to identify future research needs related to cardiovascular
pharmacogenomics.
Conference Summary
Cardiovasculardiseaseremainsthenumberonecauseofdeath
in the United States and will likely soon become the number
onecauseofdeathglobally.Atthesametime,newunderstand-
ings of individual characteristics including genetic variations
are increasingly reshaping our ability to treat various aspects
of cardiovascular disorders. The New Frontiers in Personalized
Medicine: Cardiovascular Research and Clinical Care confer-
ence brought together leaders from academia, industry, and
government to address the critical issues facing the future of
cardiovascular research and clinical care in science, business,
and policy.
Four major goals for the next 5 to 10 years were outlined
as follows: (1) to establish standards of quality for the re-
search enterprise, (2) to establish robust systems for more
rapid evidence generation, (3) to harmonize regulatory and
reimbursement standards, and (4) to develop innovative part-
nerships to accelerate the development and implementation
of personalized medicine applications. Three examples of per-
sonalized medicine that are primed for widespread clinical use
were highlighted as follows: (1) the use of pharmacogenomic
algorithms to guide the dosing of warfarin therapy; (2) the use
of blood cell gene expression proﬁles to detect or rule out
cardiac transplant rejection; and (3) the targeted sequencing
of areas of genes (resequencing) implicated in long-QT syn-
dromes to identify causal mutationsin affected individuals and
to screen family members for the same mutations.
Several new technologies with the potential to result in
new tests and new drugs were discussed, including deep
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sequencing of DNA and RNA, biomarker panels, polymerase
chain reaction technology, proteomics, and metabolomics. In
addition, strategies to bridge the much-cited “valley of death”
between basic science discoveries and development of suc-
cessful drugs included the use of genomics data to establish
the relevance of drug targets in humans before starting clini-
cal trials, the use of intermediate biomarker or imaging end-
points to make the decision to proceed with or terminate drug
candidates early in the development process, and early iden-
tiﬁcation of subpopulations most likely to beneﬁt from ther-
apy, for example, by using common genetic polymorphisms
(individually or combined into scores) or gene expression
proﬁles.
It was noted that few cardiologists report feeling knowl-
edgeable with respect to personalized medicine, highlighting
the particular need for education aimed not only at patients
but also at providers if widespread adoption of a test is to
be achieved. A number of potential solutions to overcoming
clinical and regulatory barriers to personalized cardiovascular
care were addressed, including the education of providers in
principles of basic science that are relevant to personalized
medicine; integrating personalized medicine practices into the
clinical workﬂow using electronic platforms; “real-world” stud-
ies to assess whether personalized medicine improves out-
comes when used directly in a clinical practice context; and
incentives for providers and patients to improve adherence to
personalized medicine practices.
Challenges for Cardiovascular
Pharmacogenomics
GuidedbytheproceedingsoftheNewFrontiersinPersonalized
Medicine: Cardiovascular Research and Clinical Care confer-
ence, the NHLBI Working Group characterized and discussed
challengesforcardiovascularpharmacogenomicsin5domains
as follows: clinical needs, clinical validation, information deliv-
ery,educationandcompliance,andcost-effectiveness.Forthe
purposeofdiscussion,theWorkingGroupadoptedtheInterna-
tionalConferenceonHarmonizationE15harmonizeddeﬁnition
of pharmacogenomics as “the study of variations of DNA and
RNA characteristics as related to drug response.” The majority
of the subsequent discussion focused on the study of DNA
sequence variation as related to drug response.
Clinical Needs
The Working Group sought to identify and prioritize the
most pressing clinical needs to focus research and transla-
tional efforts. In particular, 3 areas of emerging pharmacoge-
nomic applications were reviewed: anticoagulation (warfarin),
antiplatelet therapy (clopidogrel), and lipid-lowering therapy
(statins).
Warfarin
Warfarin, used widely for the prevention and treatment of
thromboembolic disease, is challenging to use because of
highly variable responses among patients and even within an
individual patient. Patients receiving warfarin anticoagulation
require frequent monitoring of blood clotting activity as mea-
sured by the prothrombin time (international normalized ratio)
particularly in the immediate period after the initiation of war-
farin therapy—with signiﬁcant risk of either thromboembolism
ifthewarfarindoseistooloworbleedingifthedoseistoohigh.
Polymorphisms in 2 genes, CYP2C9 (cytochrome P450 2C9)
andVKORC1(vitaminKepoxidereductasecomplexsubunit1),
account for more than one third of the interindividual variation
in stable therapeutic dosing of warfarin.1–5
An early small clinical trial evaluated an algorithm that in-
corporated the CYP2C9 and VKORC1 polymorphisms in an
attempt to better predict the optimal starting warfarin dose.6
When compared with the usual practice (choosing a starting
doseusingclinicaljudgment),thepharmacogenomicalgorithm
did not improve the safety of warfarin initiation—the number of
out-of-range international normalized ratios during the initia-
tion period was unchanged—although it did reduce the dosing
changes needed to achieve stable anticoagulation.6 Subse-
quent small prospective clinical trials suggested that addition
of genetic information could improve the safety and efﬁcacy of
warfarin use, particularly in guiding the choice of maintenance
dosing.7–9
Alargewarfarinpharmacogenomicsstudy,theMedco-Mayo
WarfarinEffectivenessStudywithalmost4000individuals,was
designedtotestwhethertheuseofgenotypeinformationcould
reduce the incidence of hospitalizations from warfarin-related
adverse effects.10 It was performed in a community practice
setting rather than as a randomized prospective study. In this
“real-world” study setting, CYP2C9 and VKORC1 genotypes
were determined in about 900 patients in 23 prescription ben-
eﬁt plans who were starting warfarin therapy, the genotype
data were made available to their providers (with no subse-
quent communication with the providers), and outcomes were
compared with those in 2700 historical controls in the same
23 plans for whom genotypes had not been determined. Two
external control groups from a different set of 56 plans, one
concurrentwiththegenotypedgroupandtheotherconcurrent
with the historical control group, were also followed. Within
a 6-month follow-up period, there was a 31% reduction of
hospitalization in the genotyped patients compared with the
controls, with a 28% reduction of hospitalization due to bleed-
ing or thromboembolism; there were no signiﬁcant differences
between the external control groups.10
The study design of Medco-Mayo Warfarin Effectiveness
Study has been criticized for using historical controls in-
stead of contemporaneous controls, and for the relatively slow
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turnaround time of CYP2C9 and VKORC1 genotyping, with
providers receiving this data several weeks after initiation of
warfarin. Of note, the delay in obtaining the genotyping infor-
mation indicates that the beneﬁts of the data came in guiding
maintenance dosing, rather than the initial dosing of warfarin.
Studies of alternative designs are underway, such as the Clari-
ﬁcationofOptimalAnticoagulationThroughGeneticsstudy,an
NHLBI-sponsoredprospectiverandomizedclinicaltrialthatwill
enrollupto1200participantsandcompareaclinicalalgorithm
for determining the dosing for warfarin initiation to a pharma-
cogenomicalgorithmusingCYP2C9andVKORC1genotypes.11
The results from Medco-Mayo Warfarin Effectiveness Study
and other warfarin trials suggest that anticoagulation has the
potential to be an early widely adopted pharmacogenomic ap-
plication in cardiovascular medicine. Of note, the US Food and
Drug Administration—approved label for warfarin has been re-
vised to include speciﬁc dosing guidelines for patients with
known CYP2C9 and VKORC1 genotypes. The availability of al-
ternatives to warfarin, such as the newly approved dabigatran,
also makes possible a therapeutic strategy whereby a patient
withCYP2C9andVKORC1genotypesandotherclinicalcharac-
teristics that presage higher risk for warfarin-related adverse
effectsmightbeprescribedadifferentanticoagulant,assuming
the patient does not have contraindications to that anticoagu-
lant(inthecaseof dabigatran,severerenalimpairmentorhigh
risk of bleeding).
Clopidogrel
Although dual antiplatelet therapy with aspirin and clopido-
grel is now standard therapy for acute coronary syndrome
patients,particularlythoseundergoingpercutaneouscoronary
intervention (PCI),12,13 it is clear that patients display vari-
able responses to clopidogrel therapy. A major contributor
to this variability is the common *2 loss-of-function variant
in CYP2C19, encoding a hepatic cytochrome P-450 2C19 en-
zyme important for clopidogrel bioactivation.14–16 Three large
studies of mostly post—acutecoronary syndrome and/or post-
PCI patients on clopidogrel therapy (TRITON-TIMI 38 [Trial
to Assess Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel Thrombolysis In My-
ocardial Infarction 38], FAST-MI [French Registry of Acute
ST-Elevation and Non-ST-Elevation Myocardial Infarction], and
AFIJI [Appraisal of Risk Factors in Young Ischemic Patients
Justifying Aggressive Intervention]) identiﬁed at least one
copy of CYP2C19*2 in ≈30% of individuals. In all 3 stud-
ies, reduced-function allele carriers experienced signiﬁcantly
higherratesofcardiovasculardeath,myocardialinfarction,and
stroke.17–19 Considering the totality of evidence, the US Food
and Drug Administration—approved clopidogrel label was up-
dated to include a “boxed warning” to underscore that individ-
uals carrying 2 reduced-function CYP2C19 alleles—so-called
“poor metabolizers”—experience diminished effectiveness of
the drug at standard dosing and that alternative therapeutic
strategies should be considered in these patients.
Subsequent studies have begun to clarify when clopido-
grel pharmacogenomics may be helpful in guiding therapy. A
meta-analysisof9 clopidogrelstudies withacombined 10000
participants—comprisingmostlyPCIpatients,withoverhalfbe-
ingtreatedforanacutecoronarysyndrome—foundthatcarriers
of reduced-function CYP2C19 alleles suffered a 57% increase
in risk of cardiovascular death, myocardial infarction, or is-
chemicstrokecomparedwithnoncarriers.20 Theincreasedrisk
affected carriers of 2 reduced-function CYP2C19 alleles (76%
increase) as well as carriers of 1 reduced-function CYP2C19
allele (55% increase). Notably, there was an almost tripling of
risk of stent thrombosis in reduced-function CYP2C19 allele
carriers.
In contrast, genotype data from participants in the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent Events)
and ACTIVE A (Atrial Fibrillation Clopidogrel Trial with Irbesar-
tan for Prevention of Vascular Events A) trials indicated that
the relative cardiovascular risk reduction seen with clopido-
grel treatment (vs placebo) was similar for carriers of reduced-
functionCYP2C19allelesandnoncarriers.21 However,veryfew
of the patients in either trial underwent PCI with stent place-
ment (14.5% in CURE). For participants in the PLATO (Platelet
Inhibition and Patient Outcomes) trial, in which 64% under-
went PCI with stent placement, reduced-function CYP2C19
allele carriers experienced a higher event rate on clopidogrel
than noncarriers within 30 days of initiation of therapy, but
in the long term there was no difference in the event rate on
clopidogrel.22 Together, these studies suggest that (1) the ef-
fectofreduced-functionCYP2C19allelesmaybemorerelevant
intheacutesettingratherthanthelongterm,and(2)CYP2C19
genotypingmaybemoreusefulinhigher-riskpatients(ie,those
undergoing PCI with stent placement in the setting of an acute
coronary syndrome) than in lower-risk patients.
Unlike with warfarin, there have not yet been any trials as-
sessing whether clinical decision-making informed by knowl-
edgeofCYP2C19genotypesimprovesclinicaloutcomes.Ther-
apeutic strategies that await testing include (1) giving carriers
of reduced-function CYP2C19 alleles a higher-than-standard
dose of clopidogrel or (2) giving carriers alternative thienopy-
ridinessuchasprasugrelandticagrelor.Severalhospitalshave
already begun planning for on-site, point-of-care CYP2C19
genotype testing of PCI patients in anticipation of implement-
ing one of these strategies. The relative merits of focused
point-of-care testing of acute patients versus routine pretest-
ing for CYP2C19 genotype (as well as other pharmacogenomic
data) in all at-risk patients in the outpatient setting (eg, cardi-
ology clinic) remain to be determined.
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Statins
Statins are among the most widely prescribed drugs in the
world, used for the reduction of plasma low-density lipopro-
tein cholesterol levels and the prevention of cardiovascular
disease. Development of pharmacogenomic tests that could
predict response to statin therapy might therefore have signif-
icant clinical implications. The Trp719Arg (W719R) variant of
the KIF6 (kinesin-like family 6) gene (also designated rs20455)
was identiﬁed in a small case-control study of myocardial
infarction.23 Follow-upstudiessuggestedthatthevariantmight
have value for a pharmacogenomic application. In a subset of
the WOSCOPS (West of Scotland Coronary Prevention Study)
trial, carriers of the KIF6 variant experienced greater protec-
tion against coronary heart disease with pravastatin therapy
comparedwithnoncarriers.24 IntheCARE(CholesterolandRe-
currentEvents)trial,therewasasmallerdifferenceinresponse
to pravastatin therapy between KIF6 variant carriers and non-
carriers, with the trend favoring the carriers.24 A similar trend
favoring carriers was observed in the PROSPER (Prospective
Study of Pravastatin in the Elderly at Risk) trial in subjects
with a prior history of vascular disease.25 Finally, in the PROVE
IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infec-
tion Therapy: Thrombolysis in Myocardial Infarction 22) study,
KIF6variantcarriersobtainedsigniﬁcantlygreaterbeneﬁtfrom
intensive statin therapy (atorvastatin 80 mg daily) compared
with moderate statin therapy (pravastatin 40 mg daily) than
did noncarriers.26
PublishedsubsequenttothemeetingoftheWorkingGroup,
an analysis of the HPS (Heart Protection Study) clinical trial
in subjects with a history of coronary or peripheral vascu-
lar disease found no difference between KIF6 variant carriers
and noncarriers in their response to therapy (simvastatin vs
placebo), with both groups receiving signiﬁcant beneﬁt from
statin therapy.27 A similar observation was made in a study
from the JUPITER(Justiﬁcationfor theUse of StatinsinPrimary
Prevention: An Intervention Trial Evaluating Rosuvastatin) trial,
where KIF6 W719R variant noncarriers experienced as much
protection from statin therapy (rosuvastatin vs placebo) as
did carriers.28 As has been observed for clopidogrel use in
reduced-function CYP2C19 allele carriers (as discussed pre-
viously), differences in study designs, study endpoints, risk
characteristics of the study populations, and the statin drugs
and dosages used in the various trials may account for the
conﬂicting ﬁndings with the KIF6 W719R variant. Another pos-
sibility is that the later, larger studies signify that the original
ﬁndings with the KIF6 W719R variant were simply the play of
chance.
A single variant in SLCO1B1, which encodes a hepatic up-
take transporter,has been associated witha 17-fold increased
risk of myopathy with high-dose (80 mg/d) simvastatin (see
later); the ﬁnding was replicated albeit with lower odds ratios
at a dose of 40 mg/d.29 Thus, the SLCO1B1 variant could po-
tentially be used to identify susceptible individuals in whom
to avoid the use of high-dose simvastatin; the recent US Food
and Drug Administration relabeling of the drug (to avoid the
80-mg/d dose altogether) should also reduce population risk.
Development of Further Applications
Besides the 3 areas addressed previously—anticoagulation,
antiplatelet therapy, and lipid-lowering therapy—the Working
Group noted additional areas in cardiovascular medicine for
which pharmacogenomics could potentially be of signiﬁcant
clinicalimpact,includingtreatmentofhypertension,treatment
ofheartfailure,andpredictionofthedevelopmentofcardiomy-
opathy with chemotherapeutic drugs.
The Working Group also recognized that recent advances
in human genetics have made it possible to identify many
DNA variants with potential pharmacogenomic relevance. Dur-
ing the past few years, genome-wide association studies
(GWASs) have been enormously successful in identifying vari-
ants associated with cardiovascular phenotypes, including
blood lipid levels,30,31 blood pressure,32,33 and coronary artery
disease.34,35 GWASs have also been successfully been per-
formed on medication responses, for example, the ﬁnding of
the statin myopathy—associated SLCO1B1 variant described
earlier.29 A GWAS on the response of platelet aggregation
to clopidogrel therapy identiﬁed variants near the CYP2C19
gene,36 the same gene known to harbor reduced-function al-
leles that affect clinical responses to the drug, as described
previously; conditioning the analysis on the CYP2C19*2 al-
lele eliminated the GWAS signal, indicating that this variant
drives the result. In both of these cases, the GWASs pointed
to genes already functionally linked to the drugs of interest. It
canbeanticipatedthatfutureGWASsonmedicationresponses
will implicate novel genes with unclear function, understand-
ing of which might ultimately lead to new pharmacogenomic
applications and therapeutic strategies. Accordingly, invest-
ment in GWASs and, in particular, follow-up studies on GWAS
discoveries—identifying causative genes, DNA variants, and bi-
ological mechanisms using cellular and organismal model sys-
tems, systems biology approaches, integration with bioinfor-
matics databases, targeted candidate gene resequencing, and
other methodologies—is warranted.
Clinical Validation
The Working Group noted that the gold standard for pharma-
cogenomic applications (as with all clinical interventions) is a
prospective trial with treatment determined by genotype and
withaclinicalendpointastheprimaryoutcome,butitalsorec-
ognizedthatitwouldbeverydifﬁculttosustainandfundalarge
number of such trials, and that in some cases the weight of
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evidence from observational studies may be so compelling as
to render prospective trials unnecessary. Thus, there is a need
to carefully choose which pharmacogenomic applications war-
rant funding of deﬁnitive prospective randomized trials. This
would be best served by convening expert panel meetings or
conferences to periodically evaluate the latest evidence for
several cardiovascular pharmacogenomic clinical applications
andrecommendwhethertoprovidefundingforlargeclinicaltri-
als. The Working Group also acknowledged that large trials will
not always be practical or optimal to test many potential phar-
macogenomicapplications,highlightingtheneedforinnovative
clinical trial designs to test pharmacogenomic strategies. One
such example is provided by the Medco-Mayo Warfarin Effec-
tiveness Study warfarin trial, as described previously. Another
example is to compare outcomes between community prac-
tice groups cluster randomized to pharmacogenomic strate-
gies and groups that maintain the usual practices. To promote
innovation in clinical trial design, the Working Group envisions
expert panel meetings or conferences with the express pur-
pose of devising clinical trial designs speciﬁcally suited to the
testing of pharmacogenomic strategies.
The examples of the reduced-function CYP2C19 and KIF6
W719R variants, as described previously, highlight the need
for a substantial evidence base comprising numerous stud-
ies in order to deﬁne whether a DNA variant truly predicts
a clinical outcome and, if so, which patient populations are
most likely to beneﬁt from a proposed pharmacogenomic ap-
plication using the variant. Recognizing the need for validation
studies for many future pharmacogenomic applications, the
Working Group discussed means by which to promote the in-
clusion and utilization of DNA collections in as many clinical
trials and clinical populations—that is, large cohorts with close
surveillance—as possible.
One mechanism would be for funding agencies to under-
write the costs of storage of sample collections from clinical
trialsaswellaslargehealthcaresystems(eg,oneoftheUSVet-
erans Affairs regional healthcare systems) in which electronic
record-keeping and close clinical follow-up occur, which would
empower future large-scale pharmacogenomic observational
studies. Another mechanism would entail funding agencies re-
quiringDNAbankingasaconditionforfutureclinicalstudiesto
receive funding; an alternative would be for proposed clinical
studies that include DNA banking to receive priority over clini-
calstudiesthatdonot.Athirdmechanismwouldbeforfunding
agencies to provide extra funding for studies using DNA col-
lections through existing ancillary studies programs. Finally, it
could be helpful to convene an expert panel meeting or confer-
ence in which participants would seek to achieve consensus
on the optimal use of DNA collections in pharmacogenomics
research.
Finally, the Working Group recognized that, in the inter-
est of developing a pipeline of new pharmacogenomic appli-
cations, funding would be needed for small-to-medium size
proof-of-concept clinical studies, numbering several dozen to
several hundred participants, to validate preliminary pharma-
cogenomics ﬁndings from basic science studies or post-hoc
analyses of clinical trials. This would help to screen out false-
positiveﬁndingsbeforemucheffortandresourcesaredevoted
to larger clinical studies.
Information Delivery
The Working Group identiﬁed barriers to implementation, such
as the need for fast delivery of pharmacogenomic data in the
point-of-care setting in order to enable clinical decisions, the
reliance on clinical workﬂow rules to streamline a busy clinical
schedule,andlackofutilizationevenwhenprovidersareaware
that pharmacogenomics may be helpful. Pharmacogenomic
guidelines, reference databases, and electronic platforms to
integrate personal pharmacogenomic data into the clinical
workﬂow would all be helpful in overcoming these barriers.
Innovative strategies are needed to promote the widespread
adoption of pharmacogenomic clinical applications by cardio-
vascular providers.
One such strategy would be the use of information technol-
ogy to integrate pharmacogenomics into the clinical workﬂow,
which would follow a “learning by doing” model. For example,
a provider using a computerized provider order entry system
to prescribe clopidogrel for a patient would be asked whether
thepatientisknowntohavereduced-functionCYP2C19alleles
and, if not, would be prompted to consider ordering a geno-
typing test. Extending this model, if the computerized provider
order entry were linked to the patient’s medical record and
found that the patient was known to have reduced-function
CYP2C19 alleles, the system would prompt the provider to
consider using an alternative antiplatelet medication. Thus,
preemptive genotyping—placing data in computerized provider
order entry—enabled electronic medical records—is another
strategy that needs further evaluation.
More generally, information delivery would be facilitated
by the development of a publicly available database, modeled
on the highly regarded Online Mendelian Inheritance in Man
database (http://www.ncbi.nlm.nih.gov/omim), that would
curate functional and pharmacogenomic data as well as eval-
uate the evidence related to speciﬁc DNA variants. The Phar-
macogenomics Knowledge Base (PharmGKB; http://www.
pharmgkb.org/), initially founded as part of the National In-
stitutes of Health’s Pharmacogenomics Research Network, in-
cludes as a mission to serve as a central repository from which
pharmacogenomic guidelines, reference databases, and elec-
tronic platforms could all draw. The Pharmacogenomics Re-
searchNetworkandPharmGKBhavealsoorganizedtheClinical
Pharmacogenomics Implementation Consortium37 to provide
speciﬁc evaluations of the strength of evidence for speciﬁc
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drug-gene variant relations that might support their implemen-
tation in practice; this represents another critical need in the
ﬁeld.
Education and Compliance
The Working Group recognized that many of the same barriers
and potential solutions for information delivery are relevant
to education and compliance, and that education must be
aimed not only at patients but also at providers. One means
by which to widely disseminate recommendations on phar-
macogenomic applications would be to incorporate them into
clinical guidelines, as in the Clinical Pharmacogenomics Im-
plementation Consortium effort. This could be achieved by
including cardiovascular pharmacogenomics experts on high-
proﬁle guidelines committees such as the American College of
Cardiology/American Heart Association Task Force on Prac-
tice Guidelines, the National Cholesterol Education Program,
and the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Given the
current push to encourage compliance with clinical guidelines
through a variety of incentive programs (eg, Medicare pay-for-
performance initiatives), it is to be expected that inclusion of
pharmacogenomics recommendations into clinical guidelines
would, in time, result in broad adoption of pharmacogenomic
practices.
Anotherpriorityshouldbetheestablishmentoftrainingpro-
grams in pharmacogenomics—incorporating formal training in
clinical pharmacology, genetics, biostatistics, informatics, epi-
demiology,andclinicaltrialdesign—thatcouldbesupportedby
mechanismssuchastheNationalInstitutesofHealthT32type
grants.Thiswouldserve2objectives:topromotepharmacoge-
nomics research by developing investigators with the optimal
set of skills needed to perform the research, and to create a
cohort of experts widely distributed across many institutions
who could serve as local leaders to educate others in the use
of pharmacogenomic applications.
Finally, efforts should be made to promote the training of
established clinicians as well as clinical trainees in the princi-
ples of genetics and pharmacogenomics—the former through
continuing medical education activities, the latter through cur-
ricula introduced in residency and fellowship programs.
Cost-Effectiveness
The Working Group recognized that pharmacogenomic testing
would add costs that are easy to assess but would also yield
cost savings, clinical beneﬁts, and other types of “value” that
are harder to quantify. The Working Group noted that there are
noestablishedmodelstouseinthisrelativelynewﬁeld,requir-
ing the recruitment of expertise to develop such models. This
process could be initiated by convening expert panel meetings
or conferences aimed at achieving consensus on the “best
practices” for the use of biostatistics and cost-effectiveness
analyses in pharmacogenomic studies. These models will be
essential to persuade various stakeholders to support the im-
plementation of speciﬁc pharmacogenomic applications and
to ensure that resources and efforts in clinical development
of pharmacogenetic tests (translational studies and clinical
validation) are appropriately allocated.
OneanalysisofCYP2C9andVKORC1genotype-guideddos-
ing of warfarin found that, with a cost of $400 and a 3-day de-
lay for genotyping, the marginal cost-effectiveness would be
$170 000 per quality-adjusted life-year; with a cost of $200
anda24-hourturnaroundtime,themarginalcost-effectiveness
would fall to $50 000 per quality-adjusted life-year, and geno-
typing would be cost-saving if the cost fell below $40 per
test.8 Thus, with cost-effectiveness improving as the costs as-
sociated with pharmacogenomic tests fall, it will be critical to
develop inexpensive, rapid, and extremely accurate genotyp-
ing and targeted resequencing assays for a variety of clinical
applications.Todate,thedramaticdecreaseingenotypingand
sequencing costs over the past 15 years—such that the much-
heralded “$1000 genome” is likely to become reality within
a few years—has largely been driven by high-volume research
applications (eg, GWASs of hundreds of thousands of individ-
uals, and now exome and whole-genome sequencing studies
in thousands of individuals) funded by public agencies like the
National Institutes of Health and charitable foundations like
the Wellcome Trust. It can be expected that similar sources of
fundingwillbeneededtostimulatethedevelopmentoftechnol-
ogy for low-cost pharmacogenomic tests that are appropriate
for widespread, routine clinical use or for preemptive testing
coupled to sophisticated electronic medical record systems.
Recommendations for Scientiﬁc Investment
The Working Group identiﬁed a set of research and policy
priorities designed to facilitate the development and adoption
of cardiovascular pharmacogenomics in patient care. High-
priority research programs and infrastructure needs identiﬁed
include the following:
1. Research projects targeted to high-need areas, including
the following:
(a) Small-to-medium size proof-of-concept clinical studies
(ie, several dozen to several hundred participants) to
validate preliminary pharmacogenomics ﬁndings from
basic science studies or post-hoc analyses of clinical
trials.
(b) Studies to reap the beneﬁt of GWAS locus discov-
ery by identifying causative genes, DNA variants, and
biological mechanisms using cellular and organismal
model systems, systems biology approaches, integra-
tion with bioinformatics databases, targeted candidate
gene resequencing, and other methodologies.
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(c) The development of inexpensive, rapid, and extremely
accurategenotypingandtargetedresequencingassays
for clinical use, acknowledging that current methods
are geared toward research applications rather than
clinical use.
2. Training programs for young investigators as well as es-
tablished investigators to develop skills in cardiovascular
pharmacogenomics. Such programs could include formal
training in clinical pharmacology, genetics, biostatistics, in-
formatics, epidemiology, clinical trial design, and health
outcomes and cost-effectiveness research.
3. PromotionoftheinclusionandutilizationofDNAcollections
inclinicaltrialsandforclinicalpopulationsforpharmacoge-
nomics analyses by:
(a) Providing funding for storage of sample collections.
(b) Requiring or incentivizing DNA banking for funded clin-
ical studies.
(c) Providing funding for studies using DNA collections via
the ancillary studies program.
4. Expert panel meetings or conferences to:
(a) Periodicallyevaluatethelatestevidenceforseveralcar-
diovascularpharmacogenomicclinicalapplicationsand
recommend whether to provide funding for large clin-
ical trials. An example of a clinical application that is
a high priority for evaluation is the use of CYP2C19
genotypes to guide clopidogrel therapy.
(b) Achieve consensus on the optimal use of DNA collec-
tions in pharmacogenomics research.
(c) Propose innovative clinical trial designs to test phar-
macogenomic strategies, acknowledging that large
prospective randomized clinical trials will not always
be practical or optimal to test many potential pharma-
cogenomicapplications.Anexampleistocompareout-
comesbetweencommunitypracticegroupsclusterran-
domized to pharmacogenomic strategies and groups
that maintain the usual practices.
(d) Achieve consensus on the “best practices” for the use
ofbiostatisticsandcost-effectivenessanalysesinphar-
macogenomic studies.
(e) Propose innovative strategies to promote the
widespread adoption of pharmacogenomic clinical ap-
plications by cardiovascular providers. An example is
the use of information technology to educate providers
and to integrate pharmacogenomics into the clinical
workﬂow.
5. Inclusion of cardiovascular pharmacogenomics experts on
guidelinescommitteestofacilitatetheinclusionofpharma-
cogenomics recommendations in clinical guidelines. Such
committees include the following:
(a) American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines (eg, clopido-
grel pharmacogenomics).
(b) National Cholesterol Education Program (eg, statin
pharmacogenomics).
(c) Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (eg,
beta-blocker pharmacogenomics).
6. Engagement with the US Food and Drug Administration
and other regulatory agencies to develop guidance docu-
mentsonthetypesofevidencerequiredtogainapprovalof
diagnostic biomarkers and pharmacogenomically targeted
therapies.
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